Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126 (Public Relations)

+81-3-6225-1125 (Investor Relations)

http://www.daiichisankyo.com/

## Daiichi Sankyo to Launch Percutaneous Analgesic and Anti-Inflammatory Drug Loxonin® Gel 1% in Japan

**Tokyo, Japan (October 5, 2010)** – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the launch in Japan of its percutaneous analgesic and anti-inflammatory drug Loxonin<sup>®</sup> Gel 1% (generic name, loxoprofen sodium hydrate; approval for manufacture and marketing, June 9, 2010; drug price listing, September 24, 2010).

Loxonin<sup>®</sup> Gel 1% contains the same active ingredient, loxoprofen sodium hydrate, as found in pills and powder formulations of the leading oral analgesic and anti-inflammatory Loxonin<sup>®</sup> brand. The gel offers equivalent efficacy and can be easily applied to an affected area with no displeasing odor.

Following the launch of Loxonin<sup>®</sup> pap in 2006 and Loxonin<sup>®</sup> tape in 2008, Daiichi Sankyo is confident that this new addition to the Loxonin<sup>®</sup> lineup, which has been a long-standing top brand since 1986, will further contribute to analgesic and anti-inflammatory drug treatment in Japan.

## **Product Outline**

(Launch date: October 5, 2010)

Dosage form	Percutaneous analgesic and anti-inflammatory drug
Product name	Loxonin® Gel 1% (generic name: loxoprofen sodium hydrate)
Drug price	6.8 yen/g (25g package: 170 yen, 50g package: 340 yen)  [Japan standard drug price listing received September 24, 2010]
Efficacy	Relieves pain and inflammation occurring from the following illnesses and symptoms: degenerative arthritis, muscle pain, swelling and pain caused by external injury
Dosage	Rub gel on an affected area once per day (appropriate amount dependent on symptoms)
Remarks	Manufacture and marketing: DAIICHI SANKYO Co., Ltd.